Brivaracetam

布瓦西坦

Report date: 2026/05/24 20:00:34
NME

Base Information

Drug NameBrivaracetam
Drug Alias Namebrivaracetamum布立西坦brivaracetamBrivleraRikelta +[7
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSynaptic vesicle glycoprotein 2A modulators
TargetsSynaptic vesicle glycoprotein 2A
Therapy Area/IndicationsCognitive DysfunctionNeuralgia, PostherpeticNeuralgia +[12
Global Approved IndicationsSeizuresEpilepsies, PartialEpilepsy
Approved Indications in ChinaEpilepsies, Partial
Original Approved Country/TerritoryEU
Original Approved Date2016/01/13
Country/TerritoryCzechiaBelgiumBulgaria +[47
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesUcb
China Registration ClassN/A

Develop Information

Active IndicationsCognitive DysfunctionNeuralgiaSeizures +[10
Inactive IndicationsNeuralgia, PostherpeticUnverricht-Lundborg Syndrome

Other Information

ATC CodeN03AX23